Zai Lab (HKSE:09688) EBIT per Share : HK$-2.48 (TTM As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Zai Lab EBIT per Share?

Zai Lab's EBIT per Share for the three months ended in Sep. 2024 was HK$-0.33. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 was HK$-2.48.

During the past 3 years, the average EBIT per Share Growth Rate was 0.10% per year. During the past 5 years, the average EBIT per Share Growth Rate was -9.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Zai Lab's EBIT per Share or its related term are showing as below:

HKSE:09688' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -101 Med: -29.35 Max: 0.1
Current: 0.1

During the past 9 years, the highest 3-Year average EBIT per Share Growth Rate of Zai Lab was 0.10% per year. The lowest was -101.00% per year. And the median was -29.35% per year.

HKSE:09688's 3-Year EBIT Growth Rate is ranked worse than
54% of 1250 companies
in the Biotechnology industry
Industry Median: 2.8 vs HKSE:09688: 0.10

Zai Lab's EBIT for the three months ended in Sep. 2024 was HK$-319 Mil.

Zai Lab EBIT per Share Historical Data

The historical data trend for Zai Lab's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zai Lab EBIT per Share Chart

Zai Lab Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-2.35

-2.67

-5.84

-3.19

-3.02

Zai Lab Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBIT per Share	Get a 7-Day Free Trial															-0.56	-1.09	-0.43	-0.64	-0.33

Zai Lab EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Zai Lab's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-2921.959	/	966.394
=	-3.02

Zai Lab's EBIT per Share for the quarter that ended in Sep. 2024 is calculated as

	EBIT per Share		(Q: Sep. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-318.854	/	981.687
=	-0.32

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$-2.48

Zai Lab (HKSE:09688) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Zai Lab EBIT per Share Related Terms

Thank you for viewing the detailed overview of Zai Lab's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Zai Lab Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zai Lab Ltd (HKSE:09688) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

ZLAB:USA ZLAB:Mexico 1ZLB:Germany

Address

4560 Jinke Road, Jinchuang Plaza, Building 1, 4th Floor, Pudong, Shanghai, CHN, 201210

Website

https://www.zailaboratory.com

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.

Executives

Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Wellington Management Group Llp	2102 Investment manager
Ubs Group Ag	2201 Interest of corporation controlled by you
The Capital Group Companies, Inc.	2201 Interest of corporation controlled by you
Janus Henderson Group Plc	2102 Investment manager
Du Ying	2101 Beneficial owner
Qiming Corporate Gp Iv, Ltd.
Qiming Gp Iv, L.p.
Qiming Venture Partners Iv, L.p.
Qm11 Limited
Fmr Llc	2201 Interest of corporation controlled by you
Invesco Advisers, Inc.	2102 Investment manager
Invesco Developing Markets Fund	2106 Person having a security interest in shares
Baillie Gifford & Co	2102 Investment manager
Citigroup Inc.	2502 Approved lending agent

Zai Lab Headlines

No Headlines